Search in:

Advanced search

Clinical Epidemiology Volume 8, 2016 - Issue

Submit an article Journal homepage

Open access

230

Views

CrossRef citations to date

Altmetric

Original Research

Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival

Jennifer L Beebe-Dimmer1 Department of Oncology, Wayne State University School of Medicine;2 Barbara Ann Karmanos Cancer Institute, DetroitCorrespondence[email protected]

Jon P Fryzek3 EpidStat Institute, Ann Arbor, MI

Cecilia L Yee1 Department of Oncology, Wayne State University School of Medicine;2 Barbara Ann Karmanos Cancer Institute, Detroit

Tapashi B Dalvi4 AstraZeneca, Gaithersburg, MD, USA

David H Garabrant3 EpidStat Institute, Ann Arbor, MI

Ann G Schwartz1 Department of Oncology, Wayne State University School of Medicine;2 Barbara Ann Karmanos Cancer Institute, Detroit

Shirish Gadgeel1 Department of Oncology, Wayne State University School of Medicine;2 Barbara Ann Karmanos Cancer Institute, Detroit

show all

Pages 743-750 | Published online: 26 Oct 2016

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

RayMKindlerHLMalignant pleural mesothelioma: an update on biomarkers and treatmentChest2009136388889619736192
PubMed Web of Science ®Google Scholar
TetaMJMinkPJLauESceurmanBKFosterEDUS mesothelioma patterns 1973–2002: indicators of change and insights into background ratesEur J Cancer Prev200817652553418941374
PubMed Web of Science ®Google Scholar
National Cancer Institute Surveillance Epidemiology, and End ResultsSEER*Stat software Available from: www.seer.cancer.gov/seerstatAccessed June 16, 2016
Google Scholar
MoolgavkarSHMezaRTurimJPleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005Cancer Causes Control200920693594419294523
PubMed Web of Science ®Google Scholar
RuschVWA proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest GroupLung Cancer19961411128696713
PubMed Web of Science ®Google Scholar
Van SchilPMalignant pleural mesothelioma: staging systemsLung Cancer200549Suppl 1S45S4815950801
PubMed Web of Science ®Google Scholar
CurranDSahmoudTTherassePvan MeerbeeckJPostmusPEGiacconeGPrognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experienceJ Clin Oncol19981611451529440736
PubMed Web of Science ®Google Scholar
PotoskyALRileyGFLubitzJDMentnechRMKesslerLGPotential for cancer related health services research using a linked Medicare-tumor registry databaseMed Care19933187327488336512
PubMed Web of Science ®Google Scholar
National Comprehensive Cancer NetworkNCCN guidelines for treatment of cancer by site: malignant pleural mesothelioma2015 Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.aspAccessed June 16, 2016
Google Scholar
JännePAFirst-line chemotherapy for malignant pleural mesotheliomaPassHIVogelzangNJCarboneMMalignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational TherapiesNew YorkSpringer2005593598
Google Scholar
MilanoMTZhangHMalignant pleural mesothelioma: a population-based study of survivalJ Thorac Oncol20105111841184820975379
PubMed Web of Science ®Google Scholar
MeyerhoffRRYangCFSpeicherPJImpact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results databaseJ Surg Res20151961233225791825
PubMed Web of Science ®Google Scholar
TaioliEWolfASMolineJMCamacho-RiveraMFloresRMFrequency of surgery in black patients with malignant pleural mesotheliomaDis Markers2015201528214526063951
PubMed Web of Science ®Google Scholar
BlombergCNilssonJHolgerssonGRandomized trials of systemic medically-treated malignant mesothelioma: a systematic reviewAnticancer Res20153552493250125964522
PubMed Web of Science ®Google Scholar
KrugLMWozniakAJKindlerHLRandomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesotheliomaLung Cancer201485342943425047675
PubMed Web of Science ®Google Scholar
KindlerHLKarrisonTGGandaraDRMulticenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesotheliomaJ Clin Oncol201230202509251522665541
PubMed Web of Science ®Google Scholar
VogelzangNJRusthovenJJSymanowskiJPhase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaJ Clin Oncol200321142636264412860938
PubMed Web of Science ®Google Scholar
MillensonMMLeeJHannaNHPemetrexed (Pem) plus gemcitabine (Gem) or carboplatin (Carbo) in patients (pts) with advanced malignant mesothelioma (MPM): a randomized phase II trial, E1B03J Clin Oncol20102815 Supple18053
Web of Science ®Google Scholar
SzlosarekPWSteeleJPNolanLRandomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesotheliomaJ Clin Oncol2014325 Suppl7507
Web of Science ®Google Scholar
SamsonMKWasserLPBordenECRandomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup studyJ Clin Oncol19875186913543239
PubMed Web of Science ®Google Scholar
BuikhuisenWABurgersJAVincentADThalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 studyLancet Oncol201314654355123583604
PubMed Web of Science ®Google Scholar
JassemJRamlauRSantoroAPhase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesotheliomaJ Clin Oncol200826101698170418375898
PubMed Web of Science ®Google Scholar
ZalcmanGMazieresJMargeryJBevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed (MAPS): a randomized, controlled, open-label, phase 3 trialLancet2016387100261405141426719230
PubMed Web of Science ®Google Scholar
Healthcaredeliverycancergov/[database on the Internet]Rockville, MDNational National Cancer Institute, Division of Cancer Control and Population Sciences Available from: http://healthcaredelivery.cancer.gov/seermedicare/obtain/use.htmlAccessed June 16, 2016
Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)–Medicare investigation of treatment patterns and overall survival

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date